Other
Increase (Decrease) in Accounts Receivable
Vertex Pharmaceuticals Increase (Decrease) in Accounts Receivable decreased by 140.0% to -$39.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 123.5%, from $169.60M to -$39.80M. Over 2 years (FY 2022 to FY 2025), Increase (Decrease) in Accounts Receivable shows relatively stable performance with a -3.0% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase often signals rising sales or slower collections, while a decrease suggests improved collection efficiency or declining sales volume.
Detailed definition
Measures the net change in amounts owed to the company by customers for goods or services delivered on credit. It reflec...
Peer comparison
A fundamental working capital metric used by all companies to assess cash conversion cycles.
Metric ID:
other_increase_decrease_in_accounts_receivableHistorical Data
17 periods
| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $185.30M | $43.50M | $165.20M | $84.10M | $119.50M | $0.00 | $21.03M | $21.03M | $21.03M | $21.03M | $251.60M | $51.80M | $169.60M | $18.40M | $59.90M | $99.40M | -$39.80M |
| QoQ Change | — | -76.5% | +279.8% | -49.1% | +42.1% | -100.0% | — | +0.0% | +0.0% | +0.0% | >999% | -79.4% | +227.4% | -89.2% | +225.5% | +65.9% | -140.0% |
| YoY Change | — | — | — | — | -35.5% | -100.0% | -87.3% | -75.0% | -82.4% | — | >999% | +146.4% | -32.6% | — | +15.6% | — | -123.5% |
Range-$39.80M – $251.60M
CAGR-31.9%
Avg YoY Growth+72.2%
Median YoY Growth-55.3%
Increase (Decrease) in Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's increase (decrease) in accounts receivable?
- Vertex Pharmaceuticals (VRTX) reported increase (decrease) in accounts receivable of -$39.80M in Q1 2026.
- How has Vertex Pharmaceuticals's increase (decrease) in accounts receivable changed year-over-year?
- Vertex Pharmaceuticals's increase (decrease) in accounts receivable decreased by 123.5% year-over-year, from $169.60M to -$39.80M.
- What is the long-term trend for Vertex Pharmaceuticals's increase (decrease) in accounts receivable?
- Over 2 years (2022 to 2025), Vertex Pharmaceuticals's increase (decrease) in accounts receivable has grown at a -3.0% compound annual growth rate (CAGR), from $368.80M to $347.30M.
- What does increase (decrease) in accounts receivable mean?
- The change in the amount of money customers owe the company for past purchases.